Xinjun Liang

5PUBLICATIONS
28CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersProteins and peptides
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jan 20, 2026
From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer.

Xinjun Liang, Hao Lei

|Jun 30, 2025
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.

Geoffrey Ku, Lin Shen, Farshid Dayyani

|Sep 17, 2021
Inflammation-Immunity-Nutrition Score: A Novel Prognostic Score for Patients with Resectable Colorectal Cancer.

Xin-Ying Li, Shuang Yao, Yang-Ting He

|Apr 28, 2021
Models Based on Dynamic Clinicopathological Indices for Predicting Prognosis During the Perioperative Period for Patients with Colorectal Cancer.

Yifei Ma, Ping Lu, Xinjun Liang

|May 22, 2019
<i>N</i>-Acetylcysteine Attenuates Cisplatin-Induced Acute Kidney Injury by Inhibiting the C5a Receptor.

Shuai Huang, Jian You, Kun Wang

Pageof 1

Frequent Collaborators

1 joint publications

Yanyan Liu

1 joint publications

Geoffrey Ku

1 joint publications

Lin Shen

1 joint publications

Farshid Dayyani